BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29429963)

  • 1. Impact of comorbidity on tolerability and survival following curative intent intensity modulated radiotherapy in older patients with nasopharyngeal cancer.
    Sommat K; Yit NLF; Wang F; Lim JHC
    J Geriatr Oncol; 2018 Jul; 9(4):352-358. PubMed ID: 29429963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era.
    Jin YN; Zhang WJ; Cai XY; Li MS; Lawrence WR; Wang SY; Mai DM; Du YY; Luo DH; Mo HY
    Cancer Res Treat; 2019 Jan; 51(1):34-42. PubMed ID: 29409313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy for elderly patients with nasopharyngeal carcinoma.
    Cao C; Hu Q; Chen X
    Head Neck; 2018 Mar; 40(3):590-595. PubMed ID: 29155480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up.
    Wang L; Miao J; Huang H; Chen B; Xiao X; Zhu M; Liang Y; Xiao W; Huang S; Peng Y; Deng X; Lv X; Xia W; Xiang Y; Guo X; Han F; Zhao C
    Cancer Res Treat; 2022 Jan; 54(1):118-129. PubMed ID: 34098625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
    Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
    Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
    Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
    BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
    Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y
    Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis.
    Chen J; Ding J; Xu Y; Hong H; Lin X; Xu M; Yan L; Xu T; Fei Z; Chen C
    J Geriatr Oncol; 2023 Nov; 14(8):101648. PubMed ID: 37897887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis.
    Huang XD; Zhou GQ; Lv JW; Zhou HQ; Zhong CW; Wu CF; Zheng ZQ; He XJ; Peng L; Ma J; Sun Y
    Radiother Oncol; 2018 Nov; 129(2):389-395. PubMed ID: 30270098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma.
    Guo R; Mao YP; Chen L; Tang LL; Zhou GQ; Liu LZ; Tian L; Zeng MS; Jia WH; Shao JY; Lin AH; Ma J
    Oncotarget; 2017 Feb; 8(6):10594-10601. PubMed ID: 27070084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
    Fangzheng W; Chuner J; Haiyan Q; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Peng W; Kaiyuan S; Zhenfu F; Yangming J
    Medicine (Baltimore); 2019 Dec; 98(51):e18484. PubMed ID: 31861031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study).
    Au KH; Ngan RKC; Ng AWY; Poon DMC; Ng WT; Yuen KT; Lee VHF; Tung SY; Chan ATC; Sze HCK; Cheng ACK; Lee AWM; Kwong DLW; Tam AHP
    Oral Oncol; 2018 Feb; 77():16-21. PubMed ID: 29362121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicentre UK Study of Outcomes of Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy ± Chemotherapy.
    Slevin F; Pan S; Mistry H; Sen M; Foran B; Slevin N; Dixon L; Thomson D; Prestwich R
    Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):238-249. PubMed ID: 31813661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results.
    Hu J; Bao C; Gao J; Guan X; Hu W; Yang J; Hu C; Kong L; Lu JJ
    Cancer; 2018 Jun; 124(11):2427-2437. PubMed ID: 29579324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of nasopharyngeal carcinoma with insufficient radical dose to the primary site in the intensity-modulated radiotherapy era.
    Lu T; Xie X; Guo Q; Zhan S; Lin C; Lin S; Zhang Y; Zong J; Pan J
    Head Neck; 2019 Oct; 41(10):3516-3524. PubMed ID: 31313419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: a retrospective paired study.
    Liu F; Luo T; Jin T; Zhang J; Xiang Z; Yan R; Xie L; Wu X; Zhang H; Wang F; Li P; Liu L
    BMC Cancer; 2019 Jun; 19(1):554. PubMed ID: 31176358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma.
    Hu J; Huang Q; Gao J; Guan X; Hu W; Yang J; Qiu X; Chen M; Kong L; Lu JJ
    Cancer; 2020 Dec; 126(23):5173-5183. PubMed ID: 32931035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.